Navigation Links
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
Date:6/16/2009

--Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically--

--Broad Potential Applications Include Neuropathies, Alzheimer's and Huntington's Disease and Others--

RESEARCH TRIANGLE PARK, N.C., June 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced that it has obtained the rights to develop and market a novel agent for the prevention and treatment of neuropathies and neurodegenerative disorders. The drug candidate, CXB909, is a small molecule, orally active agent that enhances the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l trial of CXB909 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) later this year.

"Nerve growth factor has long been of interest as a potential therapy for neuropathies and neurodegenerative diseases, but recombinant NGF lacks key qualities needed for successful CNS drugs," said Dr. Daniel Burch, Executive Vice President of R&D and Chief Medical Officer of CeNeRx. "In preclinical studies, our small molecule agent CXB909 has been shown to increase the action of native NGF, but without the pharmacokinetic and administration challenges of recombinant NGF. Most notably, CXB909 crosses the blood brain barrier, has a long half-life and is orally available. The preclinical data for this agent is very promising, and we look forward to assessing it in the clinic for neuropathic and neurodegenerative conditions that currently have no treatment options."

CXB909 is a downstream enhancer of the effects of nerve growth factor, an endogenously produced neurotrophic factor that is important for the function and survival of several types of neurons. Both Alzheimer's disease and Huntington's disease involve the degeneration of certain neurons, and n
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
7. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... February 26, 2015 The ... Bottle washer, Filler, Capper, Blow molder, Shrink wrapper), ... (Still, Flavored, Sparkling) & Region - Trends & ... segments the bottled water processing market with analyses ... terms of value. It also identifies the driving ...
(Date:2/26/2015)... 2015 People with psoriasis and their ... participate in research that aims to improve treatments ... psoriasis registry begins recruiting patients in 2015. ... National Psoriasis Foundation and Corrona, LLC, will initially ... new biologic medication by Novartis Pharmaceuticals for moderate-to-severe ...
(Date:2/26/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company ... announced today that Daniel P. Gold , Ph.D., President ... Company 35 th Annual Health Care Conference on Wednesday, ... Boston Marriott Copley Place. A live webcast of the presentation ... be available approximately one hour after the presentation. ...
Breaking Medicine Technology:Bottled Water Processing Market Worth $2,106.5 Million by 2019 2Bottled Water Processing Market Worth $2,106.5 Million by 2019 3Bottled Water Processing Market Worth $2,106.5 Million by 2019 4First independent U.S. psoriasis registry will track drug safety and effectiveness 2First independent U.S. psoriasis registry will track drug safety and effectiveness 3MEI Pharma to Present at Cowen and Company Health Care Conference 2MEI Pharma to Present at Cowen and Company Health Care Conference 3
(Date:2/27/2015)... GA (PRWEB) February 27, 2015 ... Martin Ventures, is collaborating with the Atlanta-based software ... the adoption of Jvion’s advanced predictive capabilities suite ... analytics company that identifies and prevents financial and ... need for predictions that help prevent patient deterioration ...
(Date:2/27/2015)... February 27, 2015 Aligned Modern ... local neighborhood health centers, officially welcomes Dr. Alaina ... based in Aligned Modern Health’s Lincoln Square, Streeterville, ... from the National University of Health Sciences and ... She has completed post-graduate coursework in functional ...
(Date:2/27/2015)... Connecticut Community for Addiction Recovery (CCAR) recently received an ... Centers (ADRC), for its shared Recovery Oriented Employment Services ... 2014 Commissioner’s Recognition Award by the CT Department of ... ROES achieved the highest rate of employment in its ... and other drug addiction. More than half of ...
(Date:2/27/2015)... GA (PRWEB) February 27, 2015 Leading ... and Consumer Protection, PartnerTech Inc. President, Gary ... Association of Georgia (TAG) for the TechAmerica DC ... leaders on legislation regarding technology along with the opportunity ... manufacturer of technology driven products, evidenced by their current ...
(Date:2/27/2015)... Bird B Gone, the leader in ... now offers an effective and humane combo of ... to this bird problem. Rarely have two new products ... problem. , Sparrow Charmer™ Bird Caller Lures them , ... broadcasting Bird B Gone’s proprietary sparrow call. Field tested ...
Breaking Medicine News(10 mins):Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 3Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 2Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 3Health News:PartnerTech Joins Technology Association of Georgia for TechAmerica DC Fly-In 2Health News:PartnerTech Joins Technology Association of Georgia for TechAmerica DC Fly-In 3Health News:New Sparrow Charmer & Sparrow Sky Trap Combo Delivers One-Two Punch to Sparrow Problem 2Health News:New Sparrow Charmer & Sparrow Sky Trap Combo Delivers One-Two Punch to Sparrow Problem 3
... International Symposium on GnRH Analogs in Cancer and ... of fertility drugs. Organon scientists have succeeded in ... hybrid subunit, which extends FSH's active life. This ... active life will mean fewer injections for the ...
... has stated that there is a metabolic threshold that ... activity becomes deleterious for lumbar bone mineral density (LBMD) ... a 10-year period, investigated the longitudinal relationship between daily ... women. They assessed LMBD, habitual daily physical activity, total ...
... of all newly-diagnosed lung cancer cases. Smoking inflicts serious damage ... people quit, as it takes time for the tissue to ... damage in the form of loss of a gene that ... of Texas have now shown that a close chemical relative ...
... the University of Rochester, New York suggests that the ... anti-coagulant properties,which until now is being used to treat ... by stroke. Researchers who conducted the study on mice ... secondary damage associated with ischemic stroke by preventing apoptosis, ...
... But it is no term to be happy about, because ... which could affect those individuals whose work or lifestyle demands ... Sitting for a long time without a break could cause ... into the lungs with possible fatal consequences. This condition is ...
... the Harvard School of Public Health now reveals that caregiving ... found that women who care for a disabled or ill ... findings were reported from a long-running Nurses' Health Study, which ... 54,412 women aged between 46 and 71. They found that ...
Cached Medicine News:Health News:New fertility drug development techniques by Organon 2
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... mounts on a standard ring stand rod ... 1/2" ) mounting rod. The 14cm (5 ... the source of fumes. A top connector ... to an aspirator or vacuum source. Tubing, ...
... These corrosion proof polypropylene exhaust hoods are ... of tanks and draw a stream of ... away from the operator. Other sizes and ... lateral, and double-slot are available on special ...
... The Benchtop Fume Hood is an ... installations in which a number of fume ... schools, junior colleges and universities. Features include ... polyethylene with rounded inside corners for easy ...
Medicine Products: